Knowing the in vitro data that have shown an involvement of ERK1/2 activation in proliferation and motility of breast cancer cells, our experiments with clinical tumour tissues have surprisingly shown opposite results since high levels of the activated kinases were associated with a better prognosis. This evidence concerns the gene MAPK3 and breast carcinoma.